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Abstract
Early phase clinical research for drug development requires the investigation of 
safety, tolerability and efficacy of novel compounds. The latter is hampered by the 
absence of the disorder in healthy volunteers, which is why challenge models are often 
applied in order to demonstrate ‘proof of pharmacology.’ These challenge models can 
often be translatable from animal work and can inform the drug developer which 
dose, dosing regimen or application frequency should be selected prior to phase II 
studies in the target population. Furthermore, these challenge models represent well-
controlled settings to perform activity screening of the compound. The following skin 
challenge models will be reviewed in this chapter: inflammation induced by Toll-like 
receptor agonists such as imiquimod, KLH challenge, UV-B irradiation and histamine.
Keywords: skin inflammation, immune system, imiquimod, translational model, 
pruritus, drug development
1. Introduction
Drug development programs are well-established and long-lasting processes, 
taking between 10 and 15 years, from discovery to market availability. Clinical trials 
with drug candidates are the final stage in drug development programs [1, 2]. These 
clinical trials are often classified into four stages of experimentation, phase I—IV, 
which are used as a general guideline in clinical trial research for development of a 
new treatment in specific diseases, i.e., skin diseases [3]. In general, safety, toler-
ability and pharmacokinetic properties are assessed in healthy volunteers during 
phase I. The candidate drug will move on to phase II when the initial safety and 
tolerability has been determined. The main aim of phase II is to establish the safety 
and efficacy of the drug in the target population. Phase III studies involve large-
scaling testing to provide more and extended information on the effectiveness of 
the drug and on the benefits and possible adverse events. The last phase, IV, also 
known as the post marketing surveillance trials, is executed after the drug enters 
the market. The main purpose of this monitoring phase is to determine the long-
term effectiveness and patient’s quality of life and cost-effectiveness [4, 5].
Translational research focuses on the transcription of the animal model into 
humans, also known as first-in-human-dose. In general, efficacy, safety and toler-
ability are examined in the early phases of clinical research. However, the absence 
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of the disorder in healthy volunteers may hamper investigation of the above-
mentioned hallmarks of drug development. Inflammation, for example, plays 
an important role in diseases and is often an indication for a certain skin disease. 
Difficulties occur when testing drugs against inflammation in volunteers who do 
not have this condition. Therefore, pharmacological challenge models have been 
established to mimic physiological and pathophysiological conditions of several skin 
diseases. These models distort the physiological condition and lead to temporary 
effects that mimic the pathophysiology of the disease.
Table 1 gives an overview of established skin challenge models.
This approach includes translating basic scientific discoveries into clinical 
applications. Several recent developments in plaque psoriasis are noteworthy, which 
serve as an example of research with many translational aspects [42, 43]. Psoriasis 
is a chronic, inflammatory skin disease that is characterized by erythematous, itchy 
plaques covered by course scales on the extensor surface of the elbows and knees, as 
well as the scalp, dorsal hands and lumbar area. Also, the nails and joints ( psoriatic 
arthritis) can be affected [44, 45]. Psoriasis is a multifactorial disease but the 
Challenge Application Mode of action Condition induced Immune response Reference
Inflammation
BCG Intradermal TLR 4, 9 
agonist
Local 
inflammation, 
systemic immune 
response
Adaptive [6–8]
Imiquimod Local under 
occlusion
TLR7 agonist Local inflammation Innate + adaptive [9–13]
LPS 
challenge + Al(OH)3
Intra dermal TLR 4 agonist Inflammatory 
response
Innate + adaptive [14, 15]
Cantharidin Paper disc with 
cantharidin
Neutrophils Local inflammation Innate [14, 16]
Injected UV killed 
E. coli
Intradermal Neutrophils Erythema, heat, 
swelling and pain
Innate [14, 17]
KLH Intradermal, 
Intramuscular
Neo-antigen Local 
inflammation, 
systemic immune 
response
Adaptive [18–22]
ITCH
Capsaicin Intradermal, 
intra muscular, 
topical
TRPV 1 
receptor
Itch Innate [23–25]
Histamine Intradermal, 
intramuscular
H1, 2, 3, 4 
receptor CMIA 
fibers
Itch Innate [26–33]
Cowhage Cutaneous CMH-fibers Itch
Burning
Unknown [34, 35]
UV-exposure
UV-B irradiation Local 
thermode
PI3K/AKT/
mTOR-
upregulation
Pain, pigmentation, 
erythema, 
inflammation
Innate
Adaptive
[23, 
36–41]
BCG: Bacillus Calmette-Guérin; LPS challenge: lipopolysaccharide; injected UV killed E. coli: Injected ultraviolet 
killed Escherichia coli; KLH: keyhole limpet hemocyanin; UV-B: Ultraviolet B.
Table 1. 
Overview of human skin challenge models.
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hallmarks of pathophysiological pathways (Th1/Th17) with interleukin-12/23 and 
IL-17 have been clearly established as most important players. Over the last decade 
many new compounds have been in development for psoriasis yielding a total of 
11 registered, targeted monoclonal antibodies today. In these drug development 
programs in vivo models in mice are of great importance for the setup of clinical pro-
grams. These mouse models needed to be made suitable to display certain features of 
psoriasis, since mice are unable to develop psoriasis themselves [10]. This research 
resulted in development of diverse mouse models i.e., spontaneous mutation model, 
genetically engineered model, cytokine injection model and transplantation model. 
All of the mentioned animal approaches represent more or less psoriasis-like cutane-
ous characteristics. Despite expression of psoriasis like features, the models also 
have some limitations including the need for special experimental facilities and lack 
of effectiveness of anti-psoriatic drugs [46–49]. In general, animal models are far 
from perfect especially in terms of pharmaco- and toxicokinetics.
Animals are not able to predict health effects in humans better than humans 
themselves. Monkeys reflects the human being the best, however, even they can 
differ as became clear in 2016. An anti-CD28 antibody caused multiple organ 
failures in six healthy volunteers within hours, despite multiple normal tests in 
monkeys. This shows that animal models may have limited predictability for safety 
in humans. Ethical concerns with regard to need for animal testing may also be a 
factor underlining the need for pharmacological challenge models in humans [50].
This chapter will provide a detailed overview of four different, local inflam-
mation models: inflammation by Toll-like receptor agonists such as imiquimod 
(inflammation), UV-B irradiation (inflammation and pain), histamine provocation 
(itch) and KLH challenge (delayed type hypersensitivity).
2. Imiquimod skin inflammation model
Skin inflammation is a common response of our immune system to penetrating 
pathogens, skin trauma, exposure of xenobiotics, microbes and parasites [51–53]. 
Inflammation is clinically recognizable by erythema, pain, heat and swelling [54]. 
Generally, in inflamed skin, various immune cells, of both the innate and adaptive 
system are involved to combat the pathogens. However, imbalance of these immune 
cells may lead to chronic skin diseases such as psoriasis vulgaris, atopic dermatitis 
and acne vulgaris. Currently, many investigations are addressing the biomolecular 
mechanisms of inflammation; however, the pathophysiology of the skin remains 
complex and needs further investigation [55, 56].
Hence, various models in healthy volunteers were developed that mimic 
inflamed skin conditions [57]. One of the examples is the challenge model 
with topical application of imiquimod, the active ingredient of Aldara cream. 
Imiquimod is a small molecule with a low molecular weight and high lipophilicity 
which is preferable for absorption in the skin after topical administration. This 
small molecule is also a ligand for toll-like receptor seven and eight (TLR), which 
belongs to the class of immunomodulatory agents and is able to induce the produc-
tion of several cytokines (interferon-1 response) with antiviral and tumoricidal 
properties. The mechanism of action of imiquimod is complex and three main 
pathways are required including TLR signaling, inflammasome activation and 
inhibition of the adenosine receptor. However, limited information is available 
on the mechanism of imiquimod on the adenosine receptor. The first pathway 
is TLR dependent and activates nuclear factor kappa B (NF-κB) signaling via 
My-D88, which is important in an early immune response. Herewith, activation of 
c-Junk and IRAK pathways occur which are involved in the production of several 
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pro-inflammatory cytokines. The second pathway is TLR independent. Imiquimod 
is able to activate the inflammasome via the NALP3 pathway, which also triggers 
an immune response and leads to production of interleukin-1β (IL-1β, a pro-
inflammatory cytokine) [10, 11, 13, 58–60].
Aldara 5% cream is registered as a topical product that is indicated for the treat-
ment of superficial basal cell carcinoma, actinic keratosis and genital and peri-anal 
warts (condyloma acuminata). Topical administration of imiquimod appears to be 
safe and reasonably tolerated according to the mouse model. This murine imiqui-
mod challenge model has been widely used to examine the mechanisms involved in 
psoriasis vulgaris, since it is simple, inexpensive and develops an acute inflamma-
tory response with psoriasiform features. However, in general, the main limitation 
of murine models is that no single mouse model is able to reflect human disease 
precisely, as the physiology and the pathophysiology of the skin differs in both 
species [61]. Therefore, recently, human studies been conducted that study skin 
inflammation after topical application of imiquimod.
Vinter et al. successfully developed an imiquimod-induced psoriasis- like skin 
inflammation model in humans by applying imiquimod topically under occlu-
sion on non-lesional psoriatic skin of the lower back. A group of patients (n = 7) 
received the treatment and vehicle for 2 days, while the other group (n = 3) received 
the same treatment for 7 days. All the treatments were applied on tape stripped 
skin resulting in perturbation of the skin barrier. After 2 days of treatment with 
imiquimod, a significant upregulation in mRNA expression was observed for the 
pro- inflammatory cytokines tumor necrosis factor a (TNF-a), IL-1β and IL-6, 
whereas TNF-a and IL-6 are keratinocyte driven cytokines. Additionally, a high 
level of IFN-γ and IL-10 was found, the latter has an important role in suppression 
of the inflammatory response in the skin, as it influences the regulatory T-cells. In 
this model, inflammation and psoriasis-like characteristics were induced; however, 
typical psoriasis lesions were not observed and therefore appear to be the main 
limitation of the study.
A different approach to study skin inflammation was established by Van 
der Kolk et al. by applying imiquimod topically to healthy volunteers under 
occlusion. A distinction between the two groups was made. The first cohort 
received a topical treatment for 24, 48 and 72 hours on the intact skin barrier, 
while the second cohort received exactly the same treatment on a compromised 
skin barrier, through tape stripping (Figure 1). In this open label, dose-ranging 
study, erythema and blood perfusion were monitored by means of erythema 
index photo analysis, erythema colorimetry, erythema visual grading and laser 
speckle contrast imaging (LSCI). A dose-dependent increase in erythema was 
observed for all measurements, with a more rapid and pronounced effect in the 
tape stripped group. This model showed no clear differences in erythema inten-
sity between the treatments after 48 and 72 hours, which is in concordance with 
observations in the murine model [9, 13]. Additionally, an increased skin perfu-
sion was found after treatment with imiquimod, however this was only observed 
in the tape stripped cohort. A similar effect was found for the biomarkers in skin 
biopsies. Tape-stripping combined with imiquimod treatment resulted in an 
upregulation of gene expression of CXCL10, MX-A, ICAM-1 and hBD-2 after 48 
and 72 hours. The same results were observed after treatment with imiquimod 
only compared to vehicle, however to a lesser extent. Imiquimod has a three-step 
mechanism, which entails an initial (24 hour), intermediate (24–72 hour) and 
late phase (>72 hour). In the intermediate phase of imiquimod, activation of 
both the innate and adaptive immune response takes place, which is character-
ized by infiltration of neutrophils, lymphocytes, and macrophages, based on the 
findings reported in the review of translational imiquimod skin inflammation 
5Pharmacological Challenge Models in Clinical Drug Developmental Programs
DOI: http://dx.doi.org/10.5772/intechopen.85352
models [59]. In addition, histologically, infiltration of CD11+, HLA-DR, CD4+ 
and CD8+ into the dermis was observed. Increased infiltration was more pro-
nounced in the tape stripped cohort, however, no differences were observed 
between 48 and 72 hours of treatment [9].
This chapter focuses mainly on translating skin inflammation into a model that 
can be used in healthy human volunteers. In the past decades, a lot of research 
has been performed in this field; however, murine models remained the gold 
standard. Since skin inflammation plays a crucial role in skin diseases such as 
psoriasis and atopic dermatitis, Vinter et al. established a human counterpart to 
the mouse model of imiquimod- induced psoriasis like skin inflammation [13]. 
Despite the expression of different pro-inflammatory cytokines and the presence 
of psoriasis-like features, typical psoriasis lesions were not observed. However, 
this study formed the base to the inflammation model developed by Van der Kolk 
et al. where imiquimod has been applied under occlusion to challenge the skin. 
This model resulted in expression of certain cytokines and chemokines that are 
involved in activation of innate as well as adaptive immune system. Chemokines 
such as CXCL10 are expressed through activation of keratinocytes in inflamed 
skin. Expression of MX-A, a downstream interferon, which corresponds with the 
activation of plasmacytoid dendritic cells (pDCs), was also upregulated in the tape 
stripped cohort. The presence of interferons reflects the antiviral response, which 
is in concordance with the antiviral characteristics of imiquimod, used for HPV-
induced diseases [62, 63]. Based on these findings, the murine imiquimod skin 
inflammation model was translated to a safe, human model in healthy volunteers. 
Skin erythema, skin perfusion and expression of cytokines had high intensity in 
the tape stripped cohort due to the enhanced transepidermal drug delivery. This 
model is suitable as a challenge model and can be used in drug developmental 
programs where TLR 7 is involved. Currently, several drugs are under development 
targeting TLR7/8 that have anti-tumor characteristics with more than 30 leads to 
be explored within the next years [64, 65].
Figure 1. 
Overview of the treatment schedule. (a) Treatment areas 1, 2 and 3 were treated with 5 mg imiquimod 
respectively for 24, 48 and 72 hours. All treatments were applied under occlusion by a 12 mm Finn chamber. 
(b) Clinical impression of site 3 of the tape stripped cohort after 72 hours of imiquimod treatment [9]. 
Permitted for non-profit use.
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3. Models for itch: histamine and cowhage provocation
Itch, interchangeably used as pruritus, is a common skin sensation and 
together with pain are crucial symptoms in many chronic and allergic skin 
diseases. Itch can be induced by mechanical, thermal and chemical stimuli. 
Additionally, itch can lead to impairment of the skin and thereby affect a per-
son’s quality of life. Yosipovitch et al. defined different types of pruritus that 
are involved in chronic itch including pruriceptive, neuropathic, neurogenic 
and psychogenic itch. Skin inflammation, dryness, or other skin damage are the 
main factors causing pruriceptive itch and are found in diseases such as scabies, 
urticaria and insect bite reactions [66, 67]. Neuropathic itch, is usually caused by 
nerve injury and can arise at any point along the afferent pathway of the neu-
rons. This itch is observed for example after a varicella zoster infection or nerve 
trauma. Itch that is originated from activation of the central nervous system is 
called neurogenic itch. The underlying mechanism is complex since it involves 
pruriceptive itch as well. This itch is often observed in visceral disease states such 
as end state renal disease or kidney failure. The last subtype of itch is termed 
psychogenic itch. This type of itch arises with somatization and the delusional 
state of parasitophobia [66–68]. In this chapter, we will focus on pruriceptive itch 
and the translational model for it.
Generally, theories have been proposed that explained the relation between 
itch and pain. Itch is mediated through weak activation of nociceptors and stron-
ger activation would result in weak pain. This is also called, the intensity theory. 
However, further research has elucidated new aspects that explain pruriceptive 
sensory mechanism in the nervous system. This resulted in two main pathways 
including specificity and pattern theories. The specificity theory, explains that there 
are different sets of neuron fibers transferring information to the central nervous 
system which send responsive signals including itch and pain [25, 35]. The pattern 
theory stipulates that many sensory receptors and spinal cord neurons are involved 
in sensation of itch [69]. Although, the neural mechanism of pruritus has been 
investigated extensively, there remains much to be learned. Therefore, studies that 
use chemical agents to induce itch have been designed to study the sensory patterns 
of itch and pain in humans.
One of the most frequently and widely used pruritic agent, that evokes itch, is 
histamine [70]. Originally, histamine is a neurotransmitter that is associated with 
pathological processes such as inflammation, pruritus and vascular leak. Histamine 
is stored in several immune cells, basophils and mast cells and is quickly released 
after stimulation. Stimulation with histamine, triggers the unmyelinated nerve 
fibers, also known as C-fibers. A subset of C-fibers (CMi or CMh) is stimulated 
according the intensity of the stimulus. In case of histamine stimulation, sustained 
response of CMi occurs [71]. Histidine decarboxylase (HDC), an enzyme that is 
responsible for histamine production, increases through stimulation with certain 
mediators that are found in skin lesions of patients with atopic dermatitis. Hence, 
this enhancement is associated with upregulated histamine release and thus with 
increased itch sensitivity [28, 70].
Histamine has been used in literature as an important inflammatory mediator 
that is responsible for vascular and inflammatory effects [33]. In the early 1900s 
the first studies were conducted regarding the potential vascular role of histamine 
in vivo, however, only a couple of years ago a clinical study was conducted that 
investigated the cutaneous inflammatory response in human skin. Falcone et al. 
has developed an easy-to-use model to study the early stages of skin inflamma-
tion. Eighteen (18) subjects with Fitzpatrick skin type II and III received topically 
applied histamine after performing histamine iontophoresis. The subject had to 
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rate their perceived itch on visual analog scale (VAS) with 3 being the threshold 
for willingness to scratch the skin. Additionally, different skin assessments were 
performed including trans-epidermal water loss, skin redness and punch biopsy to 
process immunohistochemistry. Itch was observed up to 30 minutes after stimula-
tion with histamine iontophoresis and was above the itch threshold (VAS > 3). 
Immunohistochemistry showed an increase of the epidermal thickness, after 
72 hours of histamine iontophoresis challenge. In summary, this model can be used 
as an in vivo model to provoke local and acute skin inflammation, without having 
an impact on the barrier function. However, no data are available on cell level or 
cytokine expression profiles [29].
As was earlier described, increased production of histamine has been related to 
several skin diseases including atopic dermatitis. In addition, histamine has been 
the main prototypical pruritogen that has been used for experimental purposes. 
The working mechanism of histamine is going via G- protein coupled receptors: H1 
up and till H4. It appears that the H1 and H4 receptors play a role in the histamine 
involved itch response in mice. In humans, the involvement of other receptor 
subtypes (H2 and H3) in itch is not well-examined in literature [31, 32]. Generally, 
the classical anti-histamines bind to H1 receptor and are prescribed in patients 
suffering from atopic dermatitis. However, recent research clarifies that histamine 
pathway is not playing a major role in atopic dermatitis. Also, the clinical use of 
anti-histamines in atopic dermatitis population has been ineffective and question-
able which corroborates these findings [27, 32, 72].
Therefore, there was a need to establish an alternative itch model, relating to 
another pathway. The pruritus pathway has physiological functions such as skin 
barrier homeostasis, inflammation, itch and pain and is the protease-activated 
receptor (PAR) pathway. PARs are classified as G-protein-coupled receptors and 
consist of four members, PAR-1, PAR-2, PAR-3 and PAR-4, whereas PAR-2 pathway 
is mainly associated with skin diseases such as atopic dermatitis [26]. Papoiu et al. 
established a simple human model based on exogenously stimulation of the PAR-2 
pathway in order to provoke itch by applying Cowhage spicules. Additionally, the 
Cowhage model was compared to the traditional histamine iontophoresis model 
and the effect of the combined model (histamine iontophoresis and Cowhage) was 
observed. VAS rating was increased in both atopic dermatitis patients and healthy 
volunteers, the Cowhage and combination model compared to the histamine model, 
resulting in no synergy between the Cowhage and the combined model. This 
finding suggests that Cowhage was the major contributor of itch after stimulation 
of both pathways simultaneously [34]. The Cowhage model is simple and easy to 
use and could serve to study itch related skin diseases such as atopic dermatitis. On 
the other hand, less is known about this pathway and more research is required to 
examine the mechanism behind this model.
In conclusion, two main skin challenge models were described to provoke itch: 
histamine iontophoresis and Cowhage. Both models are suitable to use, however, 
both have a different underlying mechanism to elicit the itch sensation. Evidence-
based, induction of the PAR-2 pathway plays a major role in atopic dermatitis, 
causing pruritus, compared to the histamine model. Therefore, from a therapeutic 
point of view, drugs that inhibit PAR-2 itch pathway, could be promising, leading 
to development of a new treatment for chronic pruritus. Since less is known about 
the underlying cellular mechanism of Cowhage, it would we useful to examine 
biomarker expression, conduct different skin photography assessments and look at 
the skin vascularity flow. Furthermore, an advanced challenge study is required in 
healthy volunteers and patients with atopic dermatitis to examine and monitor the 
inflammation of both models. In addition, the efficacy of anti-histamine agents and 
PAR-2 antagonists could be evaluated as well.
Translational Studies on Inflammation
8
4. Model for inflammation and pain: UV-B skin irradiation
Ultraviolet (UV) radiation is classified as a carcinogenic compound since it has 
the ability to initiate and promote malignant skin tumors. Additionally, increased 
exposure to UV radiation can lead to other skin problems such as inflammation and 
degenerative aging. UV energy is subdivided into three main classes based on physi-
cal properties: UV-A, UV-B and UV-C. UV-B can cause physiological skin alterations 
leading to a cascade of cytokine activation and resulting in an inflammatory response, 
so called “sunburn”. Furthermore, exposure to UV-B is related to the accumulation of 
epidermal keratinocytes and thereby increases the epidermal thickness. UV-B radia-
tion has an additional effect on the skin, it is able to up-regulate the production and 
the accumulation of melanin in the skin and is also linked to cancer susceptibility.
In well-controlled clinical settings, exposure to UV-B is widely used as a human 
and animal challenge model to induce local cutaneous hyperalgesia (pain) and 
inflammation. Primary hyperalgesia is induced after 24 hours and remains for more 
than 48 hours which makes the model suitable for studies where multiple dosing is 
required. The amount of UV-B radiation applied to the skin needs to be adjusted to a 
subject’s skin type, according the classification of Fitzpatrick Skin Type [73, 74].  
Hereafter, prior the start of the challenge, the Minimal Erythema Dose (MED) 
is determined and subsequently a one-, two- or threefold multiple of this dose is 
applied to the skin. After 24 hours, skin inflammation occurs.
This UV model is one of the pain models that can be used as a screening tool 
for early stage clinical drug development. However, in research, the UV model 
is used to examine the effects of anti-analgesic or local anesthetics [75, 76]. 
Recently, an article was published where the UV-B model was one of the models 
that was applied to compare the effects of several analgesic to placebo. The follow-
ing analgesic compounds were investigated in the first part: fentanyl, phenytoin, 
(S)-ketamine and placebo. For the second part of the study imipramine, prega-
balin, ibuprofen and placebo were examined. Different pharmacodynamic (PD) 
assessments were performed which are part of the pain cart including thermal 
grill, thermode testing and UV-B, electrical stimulation test, pressure stimula-
tion and cold pressure test [41]. Whilst, this study was performed to examine 
systemic effects of analgesic compounds, the topical effect of UV-B radiation was 
not determined. One article published the effects of single doses of UV-A, UV-B 
and UV-C on skin blood flow and barrier function by laser-Doppler flowmeter 
and evaporimetry. Radiation with various UV light resulted in skin inflamma-
tion characterized by erythema, however, assessed visually. Visual perception of 
erythema correlated with the increase in blood flow assessed by laser-Doppler 
flowmeter. However, UV radiation has not damaged the skin barrier function, 
since the trans- epidermal water loss was not increased. An exception formed 
the three MED, an increase in blood flow was observed after 2 weeks [38]. This 
study has examined the effects of analgesics on UV-B radiation and other models 
evoking pain, while skin inflammation occurs as well. Only a few in vivo stud-
ies attempted to examine the effect of UV-B radiation on skin inflammation. In 
general, UV-B radiation triggers the production of inflammatory cytokines in 
the human keratinocyte cell line HaCaT, including IL-1, IL-6, IL-8, IL-10 and 
TNF-a, which are leading to alterations of immune cells of the skin [39]. However, 
involvement of immune cells in skin inflammation after UV-B radiation has not 
yet been examined and monitored in healthy volunteers.
For future perspectives, the UV-B challenge model could be applied to induce 
temporarily skin inflammation that could be monitored with additional derma-
tological tests, such as multispectral imaging, thermography and laser speckle 
contrast imaging.
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5. KLH challenge
Challenge models that are described in this chapter, were mostly initiating an 
innate response, except the imiquimod challenge model. However, in auto-immune 
skin diseases, activation of the adaptive immune system is crucial as well as the 
involvement of T-cells [77]. It is quite challenging to evaluate the efficacy of novel 
drugs in healthy volunteers that target T-lymphocytes, since these are in the resting 
phase. Hence, challenge models could provide the desirable solution by activating 
autoreactive T-cell pathways in healthy volunteers. Earlier research investigated 
keyhole limpet hemocyanin (KLH) as a potential immunization candidate for 
studying the cell- mediated immune response [78]. KLH is a large molecule 
(~8000 kDa) consisting of several subtypes and has been widely used in animal and 
human research for more than 40 years to outline cellular and humoral responses 
[79–81]. Additionally, KLH can be used as a carrier protein for cancer vaccines and 
for bladder cancer immunotherapy [20, 82]. Because of the xenogeneic properties 
to the human immune system, KLH is able to promote a reliable primary immune 
response. The following administration routes are known and have been used in 
earlier research—intradermal, subcutaneous, intramuscular and inhalational  
[21, 22, 83–87]. Furthermore, KLH is considered to be clinically safe, since no 
reports are available on significant adverse events as reported in the comprehensive 
review by Harris & Markl. Only mild adverse events were reported including itch, 
rash and mild injection site reactions (soreness) [19, 88]. In summary, single dose 
immunization with KLH evokes a predictable primary T-cell dependent immune 
response. An additional intradermal dose of KLH will result in an additional 
immune response and thereby induces a delayed type IV hypersensitivity reaction 
around the site of injection [78].
Presence of erythema and induration are features of a cell-mediated immune 
response and are generally scored by visual inspection, which is a subjective 
method and may lead to significant interrater variability. Saghari et al. established 
a challenge model to activate T-cells in healthy volunteers after immunization with 
KLH, whereas both the cellular response and the delayed type hypersensitivity are 
objectively quantified. Adaptive immunity was measured by anti-KLH IgM and IgG 
blood serum level titers. Additionally, cutaneous blood perfusion, erythema and 
swelling were objectively measured by respectively laser speckle contrast imaging 
(LSCI), multispectral imaging and colorimetry. An increase in anti-KLH IgM and 
IgG was observed after intramuscular KLH administration compared to placebo. 
This was the case for the cutaneous blood perfusion quantified by LSCI and for 
the erythema and swelling quantified by multispectral imaging and colorimetry. 
So far, none of the studies have quantified induration and erythema response by 
using non-invasive instruments. This model is developed as proof-of-concept to 
determine the feasibility and to quantify the features of cell-mediated response 
[89]. Therefore, the delayed type hypersensitivity model can serve as a candidate to 
study the pharmacological and pharmacodynamic effects of immunomodulators in 
healthy volunteers.
6. Conclusion
Generally, in vivo mice models are a crucial part in pre-clinical drug develop-
mental programs, assessing safety. However, often animal models lack the disease or 
differ in morphological and physiological properties. Ethical concerns with regard 
to animal studies are an additional issue which prompts to search for new solu-
tions. Currently, safety is assessed in healthy volunteers who hamper the disease. 
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Therefore, challenge models that mimic the disease temporarily, could provide 
a possible solution and act as translational models. This chapter has provided an 
overview (Table 1) of various challenge models that are known to initiate skin 
inflammation by triggering the human immune system. First, the human imiqui-
mod challenge model was introduced as a safe and well-tolerated model to study 
temporarily induced skin inflammation by targeting the TLR7/8 receptor. The effect 
on erythema, cutaneous perfusion and biomarker expression was more pronounced 
in the group with the perturbed skin barrier due tape stripping. Nowadays, this 
imiquimod model can be applied to test agents that target TLR7/8 receptor with 
anti-tumor characteristics.
Furthermore, two models for pruritus were described focusing on two different 
mechanisms. The first model used histamine as pruritogen to evoke itch via a subset 
of C-fibers. An upregulation of HDC is associated with an increase in histamine 
release and is found in the lesions of patients suffering from atopic dermatitis. 
Anti-histamines are often prescribed against itch in patients with atopic dermatitis 
even though they are ineffective. Therefore, an alternative model was developed 
targeting the PAR-2 pathway. In this model, itch was initiated by applying Cowhage 
spicules to the forearm of healthy volunteers and patients with atopic dermatitis. 
The itch sensation was based on VAS score and EASI (in patients with atopic derma-
titis), both giving qualitative measures.
Another model that has been described in this chapter is the UV-B radiation 
model, which is used to induce pain stimulus in healthy volunteers. A couple of 
studies elucidates the occurrence of skin inflammation after UV-B radiation. 
However, no research has been done that focuses on skin inflammation in humans 
after using UV-B radiation.
The last model of this chapter triggering neo-antigen, is the KLH challenge 
model in healthy volunteers. KLH caused a delayed type IV immune response. An 
increase in cutaneous blood perfusion, erythema and swelling was observed after 
administration of KLH. This model could be used for proof-of-concept studies.
In general, all the challenge models that have been developed could be optimized 
by assessing pharmacodynamic endpoints focusing on the four pillars imaging, 
biophysical, clinical and cellular/molecular that together constitute a so-called 
‘dermatological toolbox’. For imaging, various tools can be used such as multispec-
tral imaging, 2D/3D imaging, colorimetry and optical coherence tomography. Laser 
speckle contrast imaging, trans-epidermal water loss, thermography, transdermal 
analysis patch and microbiome analyses are able to provide objective information 
on biophysical condition of the skin. For completeness of the derma toolbox it 
is recommended to include the NRS pain/itch or VAS as well as the skin histol-
ogy, immunohistochemistry and mRNA expression. This toolbox will allow us to 
develop and monitor advanced human skin challenge models that will provide a 
more holistic view and to move a step closer towards ‘systems dermatology’.
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